Kinoxis Therapeutics Pty Ltd

Amidst Australia's methamphetamine crisis, where no approved pharmacotherapies exist, we need to harness our local clinical expertise to advance Methamphetamine Use Disorder (MAUD) treatment. At the recent Biological Psychiatry Australia (BPA) conference, we hosted a symposium titled: Icy Insights: Facilitating Dialogue to Advance the Treatment of Methamphetamine Use Disorder in Australia, chaired by our Clinical Scientist, Dr Rhianne Scicluna. A/Prof Rebecca McKETIN and Dr. Krista Siefried provided an overview of the impact of MAUD on Australian communities and reviewed current interventions, from pharmacological to non-pharmacological approaches in both clinical practice and trials. A/Prof Gillinder Bedi discussed "fast-fail" approaches in clinical development and highlighted human laboratory models as a bridge between preclinical and clinical studies to improve medication translation for substance use disorders. Kinoxis’ Head of Behavioural Neuroscience, Dr. Nick Everett, spoke on the development of our lead compound, KNX100, as a potential transdiagnostic treatment for substance use disorders, including MAUD. Our symposium brought together a diverse group of experts, all tackling the challenges of MAUD from different perspectives—preclinical, clinical, and industry. Thank you again to our fantastic speakers for making this a well-rounded and impactful session! Learn more about Kinoxis Therapeutics here: https://lnkd.in/gUudDqyf #BPA2024 #MethamphetamineUseDisorder #SubstanceUseDisorders #ClinicalTrials #Biotech #IndustrySponsor #BiologicalPsychiatry

Join Our Team at Kinoxis Therapeutics! We are excited to announce that we are hiring a Senior Clinical Research Associate (SCRA) to help us drive innovative therapies forward. If you’re experienced, passionate about clinical trials and thrive in a dynamic environment, we want to hear from you!

Today, Kinoxis CEO, Hugh Alsop was honored to attend the World Mental Health Day Breakfast at Parliament House in Canberra, hosted by Boehringer Ingelheim,  the Mental Illness Fellowship of Australia (MIFA) and Psychosis Australia. This event brought together Parliamentarians, consumer advocates, healthcare professionals, and most importantly, Australians and their loved ones with lived experience. The discussions highlighted the urgent need for action to address severe and complex mental health challenges in Australia. World Mental Health Day is a critical reminder of the importance of mental well-being for everyone, with 42.9% of Australians aged 16-85 having experienced a mental disorder at some point in their lives. The need for effective treatments has never been more urgent. We stand with individuals and organizations working tirelessly to ensure mental health is understood, supported, and prioritized. As we continue to develop therapies alongside our partners at Boehringer Ingelheim, we remain dedicated to making a meaningful impact on the mental health landscape. Read more about our partnership here: https://lnkd.in/gW6nN8Wu #Dementia #SubstanceUseDisorders #NovelTreatments #Biotech #Psychiatry

We’re excited to share that Kinoxis Therapeutics Pty Ltd was a proud sponsor of this year’s International Society for Biomedical Research on Alcoholism (ISBRA) conference, held in our very own Melbourne!   Kinoxis hosted a symposium titled "Pathways to Improved Treatments for Alcohol Use Disorder," chaired by our Clinical Scientist, Dr Rhianne Scicluna. Our CSO, Professor Michael Bowen, presented data on our lead compound, KNX100—a pro-social compound with transdiagnostic potential to treat alcohol and other substance use disorders. KNX100 has shown promising results in reducing harmful drinking in both rodent and non-human primate models and has completed Phase I clinical trials.   Kinoxis is now partnering with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to evaluate KNX100 for alcohol use disorder in human trials. Read more about the partnership here: https://lnkd.in/gQmuVQu9   A big thank you to our expert speakers—Professor Katie Witkiewitz, Professor Howard Becker, and Dr. Mehdi Farokhnia—for their insights and for contributing to the discussion on advancing treatments for this complex condition.   We also want to extend our gratitude to everyone who attended and to ISBRA for hosting such a productive conference. Learn more about Kinoxis Therapeutics here: https://lnkd.in/gAjjDEM4 ISBRA Communications Committee   #ISBRA #AUD #AlcoholUseDisorder #ClinicalTrials #Biotech #SubstanceUseDisorders #NovelTherapies #NIH #NIAAA #Biotechnology  

Kinoxis Therapeutics Pty Ltd is pleased to announce the successful completion of a Series B round of capital raise. A total of $14.5 million funding has been raised through this round, led by key investors Uniseed, UniSuper, University of Sydney, Stoic Venture Capital, Avicella Capital, as well as a number of sophisticated investors.   The funds raised will be used to support Phase 2 programs for Kinoxis’ lead drug candidate, KNX100, which addresses behavioural and psychological symptoms across multiple indications, including agitation and aggression in dementia and several substance use disorders.   One of the supported programs is CARES-X, a phase 2 clinical study commencing this month. First of its kind in Australia, CARES-X will be conducted across 8 sites with 60 patients, examining the safety, tolerability and efficacy of KNX100 when used as a treatment of agitation in dementia patients.   Agitation and aggression in dementia not only have a profound impact on caregivers, but also are often the driver for the transition to assisted living facilities, resulting in a significant economic burden to the public healthcare system. Commenting on the fundraise and the CARES-X study, Kinoxis CEO Hugh Alsop said:” “This injection of funding comes at an important time. We are targeting a significant unmet treatment need for dementia patients, potentially broadening the options for them to maintain a higher quality of life. This is a new and highly promising area of development for KNX100, and we are grateful to have had the strong support from our major investors.”   Thanks also to Lis Boyce at Piper Alderman and the team at Bio101 for their support through this round.   For more details on the Series B fund raise and the CARES-X study, read the full press release via this link: https://lnkd.in/gw9Htpem #AgitationinDementia #SubstanceUseDisorder #SeriesB #BiotechInvestment

Kinoxis Therapeutics Pty Ltd is pleased to share that our CEO, Hugh Alsop has been announced as the inaugural recipient of the CEO of the Year award at The Brooker Prize gala.   The CEO of the Year award recognises individuals who have made a significant commercial, educational, member-driven or research-based contribution to their organisation or the sector. Thank you Brooker Consulting for this prestigious acknowledgment of Hugh’s contribution to the biotech and life sciences industry. As seen in this photo: John Kurek, Investor Director at Uniseed and Dr Rachel C., Principal of Brooker Consulting with Kinoxis CEO, Hugh Alsop.   #leadershipaward #biotech #lifesciences

I recently attended the College on Problems of Drug Dependence (CPDD) Conference in lovely Montreal, Canada. With drug overdoses claiming a life every five minutes in the US alone, the work of the CPDD organization is more critical than ever. Key discussions at the conference included the importance of addressing polysubstance use and the urgent need for harm reduction strategies. Innovative therapies in development were also highlighted, along with a focused discussion on drug craving—a major factor in the cycle of substance use disorders and a key contributor to relapse. By effectively treating drug cravings, we could reduce the risk of relapse to drug taking. 👩🔬 At Kinoxis Therapeutics Pty Ltd, we are making significant strides in the field of substance use disorders. #CPDD2024 #DrugDependence #SubstanceUseDisorders #AddictionResearch #Montreal #Biotech

Great to see two of our University of Sydney start ups Kinoxis Therapeutics Pty Ltd (CEO, Hugh Alsop and Prof Michael Bowen) and Endo Axiom (Dr Nicholas Hunt) in the spotlight at #BIO2024. #LeadershipForGood

Kinoxis Therapeutics Pty Ltd CEO Hugh Alsop presenting at #BIO2024 on our clinical stage programs exploring KNX100 for treating agitation and aggression in dementia and substance use disorders

Excited to the share the Kinoxis Therapeutics story at the BIO International Convention in San Diego next week. Join me for my presentation on Wednesday, June 5 at 4:00 PM in Company Presentation Theater 4. See you there. #BIO2024 Kinoxis Therapeutics Pty Ltd